**PEER-REVIEW REPORT**

**Name of journal:** World Journal of Clinical Oncology  
**Manuscript NO:** 85125  
**Title:** Targeting KRAS in pancreatic adenocarcinoma: Progress in demystifying the holy grail  
**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed  
**Peer-review model:** Single blind  
**Reviewer’s code:** 05848410  
**Position:** Peer Reviewer  
**Academic degree:** Doctor, MMed, PhD  
**Professional title:** Chief Doctor, Chief Physician, Dean, Doctor, Professor, Surgeon  
**Reviewer’s Country/Territory:** China  
**Author’s Country/Territory:** United States  
**Manuscript submission date:** 2023-04-12  
**Reviewer chosen by:** Geng-Long Liu  
**Reviewer accepted review:** 2023-04-18 08:27  
**Reviewer performed review:** 2023-04-22 14:07  
**Review time:** 4 Days and 5 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>Grade A: Excellent</th>
<th>Grade B: Very good</th>
<th>Grade C: Good</th>
<th>Grade D: Fair</th>
<th>Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Novelty of this manuscript</td>
<td>Grade A: Excellent</td>
<td>Grade B: Good</td>
<td>Grade C: Fair</td>
<td>Grade D: No novelty</td>
<td></td>
</tr>
<tr>
<td>Creativity or innovation of this manuscript</td>
<td>Grade A: Excellent</td>
<td>Grade B: Good</td>
<td>Grade C: Fair</td>
<td>Grade D: No creativity or innovation</td>
<td></td>
</tr>
</tbody>
</table>
The authors discussed the KRAS and its pathway from basic research to clinical trials. The pathway including KRAS, MEK, ERK, PI3K, and so on has been studied a lot and the drugs targeted the pathway also been studied a lot, so now there are many ongoing clinical trials. Since it is a mini-review, it is fair that the authors only placed the full informations but not discussed a lot, therefore, this manuscript does not have enough novelty. And finally, the most important issue is who is going to be the audience of this manuscript.
PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 85125

Title: Targeting KRAS in pancreatic adenocarcinoma: Progress in demystifying the holy grail

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 03765475

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Associate Professor

Reviewer’s Country/Territory: Italy

Author’s Country/Territory: United States

Manuscript submission date: 2023-04-12

Reviewer chosen by: Geng-Long Liu

Reviewer accepted review: 2023-06-15 16:35

Reviewer performed review: 2023-06-15 16:45

Review time: 1 Hour

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[Y] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade D: Fair</td>
<td></td>
<td>[ ] Grade E: Do not publish</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Novelty of this manuscript</th>
<th>[ ] Grade A: Excellent</th>
<th>[Y] Grade B: Good</th>
<th>[ ] Grade C: Fair</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade D: No novelty</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Creativity or innovation of this manuscript</th>
<th>[ ] Grade A: Excellent</th>
<th>[Y] Grade B: Good</th>
<th>[ ] Grade C: Fair</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade D: No creativity or innovation</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**SPECIFIC COMMENTS TO AUTHORS**

This is an excellent mini-review on a hot-topic in pancreatic pathology. The review is timely and well-written, with excellent tables too. The figures are very clear. Here some minor suggestions to improve this paper: 1) the readers should understand why KRAS-mutated pancreatic cancer is totally different from KRAS wild type. Please add some sentences in the Introduction section regarding the peculiarities of KRAS-wt pancreatic cancer. 2) please add some specific sentences regarding KRAS G12C (and related drugs, too) as a promising target in lung cancer patients (KRAS paragraph). Otherwise, excellent mini-review.
PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 85125

Title: Targeting KRAS in pancreatic adenocarcinoma: Progress in demystifying the holy grail

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 05469117

Position: Editorial Board

Academic degree: PhD

Professional title: Adjunct Professor, Chief Physician, Deputy Director

Reviewer’s Country/Territory: China

Author’s Country/Territory: United States

Manuscript submission date: 2023-04-12

Reviewer chosen by: Geng-Long Liu

Reviewer accepted review: 2023-06-18 17:17

Reviewer performed review: 2023-06-20 17:22

Review time: 2 Days

Scientific quality

| [ ] | Grade A: Excellent | [ ] | Grade B: Very good | [ ] | Grade C: Good |
| [Y] | Grade D: Fair | [ ] | Grade E: Do not publish |

Novelty of this manuscript

| [ ] | Grade A: Excellent | [ ] | Grade B: Good | [Y] | Grade C: Fair |
| [ ] | Grade D: No novelty |

Creativity or innovation of this manuscript

| [ ] | Grade A: Excellent | [ ] | Grade B: Good | [Y] | Grade C: Fair |
| [ ] | Grade D: No creativity or innovation |
Thank you very much for inviting me to evaluate the mini reviews titled “Targeting KRAS in Pancreatic Adenocarcinoma - Progress in Demystifying the Holy Grail”. In this article the authors summarized some of the efforts made to target the KRAS pathway which plays an important role in cancer cell proliferation, differentiation, metabolism, and survival, making it an essential mutation for targeted therapy in PC, discuss the challenges, and shed light on promising clinical trials. The information in this review may be useful to clinical communities. The paper is well arranged and the logic is clear, and the provided figure and tables are well composed and understandable. The quality of language of the manuscript is quite acceptable for me. But this article has “obvious differences”:

1) Viewpoints involved in the article lacks a comprehensive discussion, and directly uses examples for discussion.
2) The treatment methods mentioned explain the mechanisms, but do not give specific efficacy data, which is puzzling.

So, I recommend that this manuscript may be accepted after major revision. Here is a question for the authors. Please systematically explain how KRAS mutations drive tumor progression and possible drug resistance mechanisms, which is an important part of your review.
of the discussion on this topic?
# RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** World Journal of Clinical Oncology  
**Manuscript NO:** 85125  
**Title:** Targeting KRAS in pancreatic adenocarcinoma: Progress in demystifying the holy grail  
**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed  
**Peer-review model:** Single blind  
**Reviewer’s code:** 05469117  
**Position:** Editorial Board  
**Academic degree:** PhD  
**Professional title:** Adjunct Professor, Chief Physician, Deputy Director  
**Reviewer’s Country/Territory:** China  
**Author’s Country/Territory:** United States  
**Manuscript submission date:** 2023-04-12  
**Reviewer chosen by:** Cong Lin  
**Reviewer accepted review:** 2023-07-07 15:02  
**Reviewer performed review:** 2023-07-07 15:51  
**Review time:** 1 Hour

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[Y] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
<th>[ ] Grade D: Fair</th>
<th>[ ] Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>[Y] Grade A: Priority publishing</td>
<td>[ ] Grade B: Minor language polishing</td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>[ ] Accept (High priority)</td>
<td>[Y] Accept (General priority)</td>
<td>[ ] Minor revision</td>
<td>[ ] Major revision</td>
<td>[ ] Rejection</td>
</tr>
<tr>
<td>Peer-reviewer</td>
<td>Peer-Review: [Y] Anonymous</td>
<td>[ ] Onymous</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS

The revised article can be accepted for publication